Open AccessTo what extent can mathematical modeling inform the design of clinical trials? The example of safe dose reduction of tyrosine kinase inhibitors in responding patients with chronic myeloid leukemia
Author(s) -
Joshua T. Schiffer,
Charles A. Schiffer
Publication year - 2018
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2018.201897
Subject(s) - myeloid leukemia , clinical trial , tyrosine kinase , medicine , tyrosine kinase inhibitor , reduction (mathematics) , pharmacology , cancer research , oncology , intensive care medicine , cancer , receptor , geometry , mathematics